Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Natasha on +44 1494 818 053 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Natasha Wilson
Executive Recruiter
+44 1494 818 053

I could not speak more highly of Zenopa for all the help and advice they have given me on how to strengthen my candidacy enabling me to get my foot in the door of medical communications.
Sofia, 2014

Bayer HealthCare announces positive Nexavar thyroid cancer data

3 January 2013 11:28 in Pharmaceutical Company Product News

Bayer HealthCare and partner Onyx Pharmaceuticals have unveiled new clinical trial data showing the potential of Nexavar tablets to treat a certain form of cancer.

Results from the phase III Decision study demonstrated that Nexavar delivered progression-free survival benefits among patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer.

The safety and tolerability profiles of the drug were also shown to be positive, suggesting Nexavar could be an effective therapy for a condition for which there are currently limited options available.

Bayer plans to submit the Decision data to support marketing authorisation applications for Nexavar in the treatment of RAI-refractory differentiated thyroid cancer.

Dr Dimitris Voliotis, vice-president for global clinical oncology development at Bayer HealthCare, said: "We are pleased that the results of this study demonstrate that Nexavar may provide a treatment option for these patients."

This comes after the firm submitted radium-223 dichloride for European approval in the treatment of castration-resistant prostate cancer last month.ADNFCR-8000103-ID-801515813-ADNFCR

Other news stories from 03/01/2013

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd